Tara E Seery, Aditi Choudhry, Ann Eapen, Yu Cheng
A physician should contemplate systemic therapy when patients are symptomatic, have significant tumor burden, or disease progression. Each patient and tumor is unique and there is no consensus on treatment sequencing and which regimen is the best. Over the past few years, a number of new agents are now approved for pancreatic neuroendocrine tumors and the treatment field has dramatically expanded. Our review will discuss the key agents and focus on the newer regimens. The treatment options range from sandostatin analogues, targeted treatments, and chemotherapy. We always recommend a multi-disciplinary team to help guide the treatments for pancreatic neuroendocrine tumors patients.
